<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(9)</volume><submitter>Fratoni AJ</submitter><pubmed_abstract>Patients hospitalized with coronavirus disease 2019 (COVID-19) often receive empiric antibiotic coverage. Procalcitonin (PCT) is a biomarker with Food and Drug Administration-approved guidance cutoffs for antibiotic use in lower respiratory tract infections. Herein we describe the implementation and impact of a pharmacist-managed PCT monitoring program in hospitalized patients with COVID-19. In this quasi-experimental, single-center, retrospective study of a prospective antimicrobial stewardship pharmacist-managed program, inpatients who were severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction positive were reviewed during weekday working hours and evaluated for appropriateness of antibiotic treatment by utilizing the PCT biomarker. As needed, the infecti</pubmed_abstract><journal>Open forum infectious diseases</journal><pagination>ofac468</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9494375</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Impact of a Pharmacist-Managed Procalcitonin Program on COVID-19 Respiratory Tract Infection Outcomes and Health Care Resource Utilization.</pubmed_title><pmcid>PMC9494375</pmcid><pubmed_authors>Nicolau DP</pubmed_authors><pubmed_authors>Fratoni AJ</pubmed_authors><pubmed_authors>Kois AK</pubmed_authors><pubmed_authors>Linder KE</pubmed_authors><pubmed_authors>Colmerauer JL</pubmed_authors><pubmed_authors>Kuti JL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of a Pharmacist-Managed Procalcitonin Program on COVID-19 Respiratory Tract Infection Outcomes and Health Care Resource Utilization.</name><description>Patients hospitalized with coronavirus disease 2019 (COVID-19) often receive empiric antibiotic coverage. Procalcitonin (PCT) is a biomarker with Food and Drug Administration-approved guidance cutoffs for antibiotic use in lower respiratory tract infections. Herein we describe the implementation and impact of a pharmacist-managed PCT monitoring program in hospitalized patients with COVID-19. In this quasi-experimental, single-center, retrospective study of a prospective antimicrobial stewardship pharmacist-managed program, inpatients who were severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction positive were reviewed during weekday working hours and evaluated for appropriateness of antibiotic treatment by utilizing the PCT biomarker. As needed, the infecti</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-04-27T03:03:18.72Z</modification><creation>2025-02-19T02:24:47.532Z</creation></dates><accession>S-EPMC9494375</accession><cross_references><pubmed>36176570</pubmed><doi>10.1093/ofid/ofac468</doi></cross_references></HashMap>